Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has shared an announcement.
Hikma Pharmaceuticals has continued executing its previously announced $250 million share buyback, repurchasing 192,000 ordinary shares on 2 March 2026 on the London Stock Exchange at a volume-weighted average price of 1,257.79 pence. The company plans to cancel these shares, bringing total purchases since 26 February to 472,000 shares at a cost of £6.2 million and leaving 221,414,453 voting shares in issue, a move that reduces share capital and may enhance earnings per share for remaining investors.
The most recent analyst rating on (GB:HIK) stock is a Sell with a £13.50 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. It focuses on developing, manufacturing and marketing injectable, branded and non-branded generic medicines for global markets, with a strong presence in the U.K. and Middle East.
Average Trading Volume: 1,010,435
Technical Sentiment Signal: Sell
Current Market Cap: £3.06B
For detailed information about HIK stock, go to TipRanks’ Stock Analysis page.